UBS Group reaffirmed their reduce rating on shares of Infinity Pharmaceuticals (NASDAQ:INFI) in a research report sent to investors on Monday, The Fly reports.
A number of other equities research analysts also recently issued reports on INFI. Zacks Investment Research upgraded Infinity Pharmaceuticals from a hold rating to a buy rating and set a $3.00 price objective on the stock in a research report on Tuesday, September 25th. JPMorgan Chase & Co. downgraded Infinity Pharmaceuticals from a neutral rating to an underweight rating in a research report on Monday, November 12th. Wells Fargo & Co downgraded Infinity Pharmaceuticals from an outperform rating to a market perform rating in a research report on Monday, November 12th. Finally, B. Riley started coverage on Infinity Pharmaceuticals in a research report on Friday, January 4th. They set a buy rating and a $3.00 price objective on the stock. Two analysts have rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company’s stock. Infinity Pharmaceuticals has a consensus rating of Hold and a consensus target price of $2.83.
NASDAQ:INFI opened at $1.29 on Monday. The stock has a market capitalization of $70.51 million, a P/E ratio of -1.55 and a beta of 2.29. Infinity Pharmaceuticals has a 12 month low of $1.00 and a 12 month high of $2.92.
In other Infinity Pharmaceuticals news, major shareholder Bvf Partners L. P/Il purchased 91,474 shares of Infinity Pharmaceuticals stock in a transaction dated Thursday, November 15th. The shares were purchased at an average cost of $1.35 per share, for a total transaction of $123,489.90. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Value Fund L. P. Biotechnology purchased 100,000 shares of Infinity Pharmaceuticals stock in a transaction dated Wednesday, November 28th. The stock was acquired at an average price of $1.30 per share, for a total transaction of $130,000.00. The disclosure for this purchase can be found here. Over the last quarter, insiders bought 3,905,634 shares of company stock worth $5,300,055. Company insiders own 11.45% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of INFI. Northpointe Capital LLC purchased a new stake in shares of Infinity Pharmaceuticals in the third quarter worth approximately $1,433,000. Fosun International Ltd bought a new position in Infinity Pharmaceuticals in the third quarter worth approximately $879,000. Opaleye Management Inc. bought a new position in Infinity Pharmaceuticals in the third quarter worth approximately $745,000. Essex Investment Management Co. LLC grew its stake in Infinity Pharmaceuticals by 121.4% in the third quarter. Essex Investment Management Co. LLC now owns 364,401 shares of the biotechnology company’s stock worth $988,000 after purchasing an additional 199,796 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in Infinity Pharmaceuticals by 27.0% in the second quarter. Dimensional Fund Advisors LP now owns 932,370 shares of the biotechnology company’s stock worth $1,781,000 after purchasing an additional 198,098 shares in the last quarter. Hedge funds and other institutional investors own 52.16% of the company’s stock.
About Infinity Pharmaceuticals
Infinity Pharmaceuticals, Inc, a biopharmaceutical company, develops medicines for people with cancer in the United States. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study.
Read More: Market Capitalization in the Stock Market
Receive News & Ratings for Infinity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.